Background {#Sec1}
==========

In recent years the spread of vector borne diseases has gained concern worldwide, especially in tropical and subtropical regions because of their recurring outbreaks \[[@CR1]\]. Some of these diseases have become endemic in many areas causing millions of cases every year \[[@CR2]\]. The most common of these diseases includes Malaria, Dengue and Chikungunya spread by mosquito bites. Malaria has been long recognized as a significant public health threat with around 212 million cases reported in 2015 alone \[[@CR3]\]. Malaria is caused by five different species of Protozoal parasite, *Plasmodium*. These include *P. falciparum, P. ovale, P. malariae, P. vivax and P. knowlesi* that are carried and spread by *Anopheles* mosquito \[[@CR4], [@CR5]\]. Dengue and Chikungunya are caused by viruses named Dengue virus (DENV) and Chikungunya virus (CHIKV) respectively. Both are spread by common mosquito vectors *Aedes s p.* Dengue viruses have four serotypes DENV-1, 2,3 and 4 \[[@CR6]\]. As many as 400 million people are affected with Dengue every year \[[@CR7]\]. Chikungunya follows somewhat unique pattern of spread across the world, it has the potential to emerge and re-emerge, drastically affecting a population and then remaining undetected for years \[[@CR8]\]. In recent years many tropical countries have seen an unexpected rise and spread in cases of Dengue and Chikungunya \[[@CR9]\].

These three vector borne diseases share an overlapping epidemic pattern with most cases reported from tropical regions of the world. Several studies have been published reporting co-circulation of Malaria, Dengue and Chikungunya \[[@CR10], [@CR11]\]. Apart from shared endemicity, the three diseases also share similar clinical presentation with febrility as the most common symptom. There are several distinguishing features also, like periodic increase and decrease of fever in Malaria, hemorrhagic conditions and depletion of platelet count in Dengue and severe arthralgia in case of Chikungunya infection \[[@CR12], [@CR13]\]. The cumulative burden of these infections has increased in recent times with frequent outbreak of Dengue and Chikungunya being reported from several parts of the world. Global travel and rapid urbanisation are important factors that have contributed in expansion of disease endemicity by introducing the vector population to exotic surroundings \[[@CR14]\].

Simultaneous infections with more than one infectious agent complicate the diagnosis and course of treatment available. Due to the similar nature of initial symptoms for Malaria, Dengue and Chikungunya and overlapping endemicity, misdiagnosis of dual infection as monoinfection is a real possibility. Indeed several reports have been published reporting such scenarios. These arthropod borne diseases affect some of the poorest countries and in resource poor settings; clinician might rely on symptoms and endemicity for diagnosis, which might lead to underdiagnosis of cocirculating pathogens \[[@CR15]\]. Despite similar clinical presentation the course of treatment is entirely different for all three diseases. Malaria is treated using antimalarial drugs. In case of Dengue and Chikungunya no vaccine or drug is available and clinicians rely on supportive therapy \[[@CR13], [@CR16]\]. Any delay in either diagnosis or start of therapy for any of these infections could have fatal outcomes. Also, there is lack of sufficient information on how concurrent infections affect disease severity and outcome. Several studies have been published that report cases of concurrent infection with two of these pathogens and in rare instances concurrent infection with all three vector borne infections. Such reports have the potential to inform public health officials and clinicians about the prevalence, disease severity and treatment options available for concurrent infections. The purpose of the present review is to assess the prevalence of such infections by thorough search and analysis of published literature.

Methodology {#Sec2}
===========

Search strategy {#Sec3}
---------------

We did a review based on PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines to identify all relevant publications pertaining to the prevalence of Malaria, Dengue and Chikungunya coinfection. We systematically searched PubMed and Web of Knowledge from inception up to April 2018, using the following search terms anywhere in the articles: Malaria AND Dengue or Malaria AND Chikungunya or Dengue AND Chikungunya. We searched without any bar on language, publication or nature of studies. To identify additional studies, reference list of publications were carefully screened.

### Eligibility criteria {#Sec4}

Initial assessment was based on review of title and abstract of all studies. Full texts of potentially relevant studies were further analysed for coinfection prevalence data. Cross-sectional studies, retrospective analysis and case reports with full text availability and reporting data about any/all of the coinfections were included in the study. We excluded studies carried out in animals, reviews, letters, opinion pieces, grey literature, dissertations and conference abstracts.

### Data extraction {#Sec5}

The data extracted from the selected publications included first author, date of survey, place where the study was carried out, sample size and age, type of diagnostic testing performed, study design and prevalence of coinfection. All the data was entered in an excel file and double-checked.

Prevalence mapping {#Sec6}
------------------

The extracted data was used to create a map of prevalence of coinfection cases. All the cases reported were from seven geographical locations, South Asia, Africa, Southeast Asia, South America, North America, Caribbean and the Middle East. A total of 19 countries reported cases of Malaria/Dengue coinfection; while 24 countries reported coinfection cases of Dengue/Chikungunya. Malaria/Chikungunya cases were reported from 6 countries. Malaria/Dengue/Chikungunya coinfections were reported from only 3 countries. The maps were created using openly available maps (<https://www.freeworldmaps.net>).

Results {#Sec7}
=======

We were able to identify 109 publications that reported the data for any coinfections (Fig. [1](#Fig1){ref-type="fig"}, Additional file [1](#MOESM1){ref-type="media"}: Table S1). The full text of 104 publications were available out of which 48 were cross sectional studies, 37 were case reports, 13 were retrospective analysis, 5 were prospective studies and 1 surveillance report \[[@CR17]--[@CR120]\]. 49 studies reported only Malaria/Dengue coinfections (Table [1](#Tab1){ref-type="table"}) while 44 studies reported only Dengue/Chikungunya coinfections (Table [2](#Tab2){ref-type="table"}). 1 study reported only Malaria/Chikungunya infection. 3 studies reported both Malaria/Dengue and Malaria/Chikungunya coinfections (Table [3](#Tab3){ref-type="table"}) and 1 study reported Malaria/Dengue, Dengue/Chikungunya and Malaria/Chikungunya coinfections. Malaria/Dengue/Chikungunya coinfections were reported by 4 separate studies (Table [4](#Tab4){ref-type="table"}). 2 studies reported Malaria/Dengue, Dengue/Chikungunya, Malaria/Chikungunya and Malaria/Dengue/Chikungunya coinfections. All of the studies, except two, were published after year 2005. Cases of coinfections were reported from all age groups and two studies from India and Burma reported data from only pregnant females. Blood smear was the most prevalent method for detection of Malaria parasite, while NS1 (Non-structural protein-1) and immunoglobulin ELISA were the most common methods for the detection of Dengue. IgM ELISA was the predominant method for the detection of most cases of Chikungunya. In 14 studies *P. falciparum* was the cause of Malaria while another 13 reported *P. vivax* as the infecting species alongside coinfecting arbovirus. 12 studies reported both *P. falciparum* and *P. vivax* with Dengue virus in the same population. Another 5 studies reported *P. falciparum*, *P. vivax* and Dengue virus in the same individuals. *P. knowlesi* was reported by two studies and *P. ovale* was reported by one study.Fig. 1Schematic representation of the study selection processTable 1Coinfection cases of Malaria and DengueS.No.CitationPlaceYearStudy designNPositive for coinfectionCoinfection (%)AgeDiagnostic test ML/DNRemarksSouth Asia1Abbasi \[[@CR17]\]Karachi,\
PakistanSept.2007-Jan. 2008Cross sectional112262313--70Blood smear / IgM and IgG ELISA*P. vivax- 25,  P. falciparum*- 12Ahmad \[[@CR18]\]Uttarakhand, IndiaDec 2012-Dec2013Retrospective observational studies23393.838.6 ± 16Blood smear/ IgM ELISANM3Alam \[[@CR19]\]Patna,\
India2013Case report11NA42Blood smear /NS1, IgM and IgG ELISA*P. falciparum*4Ali \[[@CR20]\]Rawalpindi,\
PakistanNov. 2003-Oct. 2004Cross sectional8009117--50 yearsBlood smear /IgM ELISA*P. vivax-8, P. falciparum-1*5Arya \[[@CR21]\]Delhi,\
India2003Case report22NA35 and 63 yearsBlood smear /IgM ELISA*P. vivax*6Assir \[[@CR22]\]Lahore,\
PakistanAug- Nov 2012Cross sectional85617212--32Blood smear /PCR, NS1 and IgM ELISA*P. vivax* - 14, *P. falciparum*-37Barua \[[@CR23]\]Mumbai,\
IndiaJune-Nov. 2014, June -Nov. 2015Retrospective analysis573448NMBlood smear / NS1 and IgM ELISANM8Bhagat \[[@CR24]\]Mumbai,\
India2014Case report33NA8 months −12 yearBlood smear, RDT/NS1, IgM and IgG ELISA*P. vivax*9Bhalla \[[@CR25]\]Delhi,\
India2006Case report11NA21Blood smear /IgM ELISA*P. falciparum*10Chander \[[@CR26]\]Chandigarh,\
India2009Case report11NA28Blood smear /IgM ELISA*P. falciparum*11Deresinski \[[@CR27]\]USA, infected in India2003, DecCase report11NA27Blood smear/IgM and IgG ELISA*P. vivax*12Faruque \[[@CR28]\]Chittagong,\
BangladeshDec. 2008-Nov. 2009Cross sectional72010.1All agesRDT/IgM ELISA*P. vivax*13Hati \[[@CR29]\]Kolkata,\
IndiaAug 2005-Dec 2010Cross sectional2971461.5NMBlood smear /IgM and IgG ELISA*P. vivax*-28, *P. falciparum*-1814Kaushik \[[@CR30]\]Dehradun,\
India2006Case report11NA26Blood smear/ IgM and IgG ELISA*P. vivax* + *P. falciparum*15Malhotra \[[@CR31]\]Patiala,\
India2012Case report11NA27Blood smear /NS1 and IgM ELISA*P. vivax*16Mittal \[[@CR32]\]Dehradun, IndiaDec 2012- Nov 2013Retrospective observational study254780.3Above 18Blood film, RDT/IgM, NS1 ELISANM17Mohapatra \[[@CR33]\]Odisha,\
IndiaJune-Sep 2011Prospective observational study469276NMBlood smear /IgM and NS1 ELISA*P. falciparum*-24, *P. vivax* -- 2, *P. falciparum* + *P. vivax* - 118Mørch \[[@CR34]\]Assam,  Bihar, Chhattisgarh, Maharashtra, Anantpur Tamilnadu\
IndiaApril 2011--November 2012Cross sectional1564583.734 mean ageBlood smear/IgM, NS1 ELISA/NM19Mushtaq \[[@CR35]\]Srinagar, infected in Delhi,\
IndiaOct - 2012Case report11NA25Blood smear, RDT/ IgM ELISA*P. falciparum* + *P. vivax*20Pande \[[@CR36]\]Meerut,\
India2013Case report11NA25Blood smear /NS1 and IgM ELISA*P. falciparum, P. vivax*21Raja \[[@CR37]\]Chennai,\
IndiaMay 2013- Jan 2014Cross sectional10033NMBlood smear/ELISANM22Rani \[[@CR38]\]Hyderabad, India2015Case report11NA30sBlood smear/IgM ELISANM23Rao \[[@CR39]\]Odisha (Angul), IndiaJan-Dec 2013Cross sectional1980221All agesBlood smear, RDT/ IgM and NS1 ELISA, PCR*P. falciparum*- 12, *P. vivax-* 1024Singh \[[@CR40]\]Dehradun, IndiaJuly-Nov 2013Retrospective114190.812--80Blood smear/IgM, NS1 ELISANM25Saksena \[[@CR41]\]Delhi,\
India2017Case report11NA17 maleRMAT, PCR/IgM ELISA*P. vivax, P. falciparum*26Singla \[[@CR42]\]Chandigarh, IndiaJan 2011-Dec 2012Cross sectional30010.3NMNM/NS1 and IgM ELISA*P. vivax*27Shah \[[@CR43]\]Ahmedabad, IndiaJune 2013-Nov 2014Retrospective8364270.3NMBlood smear/NS1, IgM ELISA*P. vivax* + DENV-17, *P. falciparum* + DENV-9,\
P. *falciparum* +  P. *vivax* + DENV-128Thangaratham \[[@CR44]\]Alappuzha,\
Kerala2006Case report11NM22Blood smear /IgM ELISA*P. vivax,* DENV229Yasir \[[@CR45]\]Karachi,\
PakistanApril 2013-Jan 2014Cross sectional1595315--53 yearsBlood smear /IgM ELISANMAfrica30Ayorinde \[[@CR46]\]Ogun, NigeriaApril-May 2014Cross sectional6012All agesBlood smear, RDT, PCR/NS1, IgM and IgG ELISA*P. falciparum*31Baba \[[@CR47]\]NigeriaJuly-Dec. 2008Cross sectional310186All agesBlood smear /PRNT*P. falciparum*32Charrel \[[@CR48]\]France, infected in Guinea, Senegal and Sierra Leone2004, marchCase report11NA37Blood smear /IgM and IgG ELISA*P. falciparum,* DENV333Chipwaza \[[@CR49]\]Morogoro, TanzaniaMarch--May and Aug-Oct. 2013Cross sectional3643192--13Blood smear /IgM and IgG ELISA, PCRNM34Dariano \[[@CR50]\]Bo, Sierra Leone2012--2013Cross sectional126030.2All agesRDTs/IgM, IgG, NS1 ELISANM35Kolawole \[[@CR51]\]Ilorin,\
Nigeria2016Cross sectional17653All agesRDT/IgM ELISA, PCRDENV2, DENV3, DENV436Oyeoro \[[@CR52]\]Ibadan, NigeriaJan-April 2013Cross sectional1881910All agesNM/IgG, IgM, NS1 ELISANM37Sow \[[@CR53]\]Kedougou, SenegalJuly 2009--March 2013Cross sectional13,84510.01All agesBlood smear, RDT/ IgM ELISA, PCR*P. falciparum*38Stolar \[[@CR54]\]Ghana2011--2014Retrospective analysis218732--14 yearsRDT/IgM and IgG, ELISA, PCR*P. falciparum*39Vu \[[@CR55]\]Kenya2016Cross sectional5793361--17 yearsBlood smear /PCRNMCaribbean40Serre \[[@CR56]\]Spain,\
Infected in Haiti2011Case report11NA27Blood smear, PCR/IgM, IgG and NS1 ELISA, PCR*P. falciparum,* DENV4Southeast Asia41Che rahim \[[@CR57]\]Kelantan, Malaysia2017Case report11NA59Blood smear, PCR/NS1 ELISA*P. knowlesi*42Chong \[[@CR58]\]Malaysia2017Case report11NA59Blood smear/NS1 and IgM ELISA*P. knowlesi*43Issaranggoon \[[@CR59]\]Thailand2014Case report11NA11Blood smear/ NS1, IgM ELISA*P. falciparum*44McGready \[[@CR60]\]Thai-Burmese borderJan 2004-May 2006Cross sectional20910.5Pregnant womenBlood smear/IgM ELISA, NS1 ELISA*P. falciparum, P. vivax*45Mueller \[[@CR61]\](Oun Kouma, Ou Chra, Snoul)\
Rural CambodiaJan 2008- Dec 2010Prospective observational study1193302.57--49 yearsRDT/PCR*P. falciparum, P. vivax*46Thaha \[[@CR62]\]Surabaya, IndonesiaNov 2008Case report11NANMBlood smear/IgM, IgG ELISANM47Ward \[[@CR63]\]East Timor2006Case report11NA7Blood smear /IgM ELISA*P. falciparum*48Yong \[[@CR64]\]Riau Island Indonesia2012Case report11NA49Blood smear/IgM, NS1 ELISA*P. falciparum*South America49Carme \[[@CR65]\]French GuianaJuly 2004-June 2005Retrospective analysis1723171NMBlood smear/PCR, IgM ELISA, virus isolation*P. vivax* − 14, *P. falciparum*- 3, DENV3--5, DENV1--1, NM-1150Epelboin \[[@CR66]\]French Guiana2004--2010Retrospective matched pair studyNM104NAAll agesBlood smear/PCR, NS1, IgM, IgA ELISA*P. vivax* -- 80, *P. falciparum* -- 21, *P. vivax* + *P. falciparum* -- 3, DENV1--3, DENV2--2, DENV3--5, NM-9451Lupi \[[@CR67]\]Rio de Janeiro, BrazilApr 2013Case report11NA52Blood smear, RDT, PCR/ IgM and NS1 ELISA, PCR*P. ovale wallikeri*52Magalhaes \[[@CR68]\]Brazilian Amazon\
Manaus\
BrazilMarch 2009 to April 2010Retrospective study132118Mean age, 42.7 yrsBlood smear, PCR/NS1 ELISA, PCR*P. vivax* DENV2, DENV3, DENV453Magalhaes \[[@CR69]\]Brazilian Amazon\
Manaus\
Brazil2009--2011Cross-sectional1578443All agesBlood smear, PCR/ NS1 ELISA, PCR*P. vivax*54Mendonca \[[@CR70]\]Brazilian Amazon\
Manaus\
Brazil2009--2013Prospective observational studyAll febrile patients30NA31.11 median ageBlood smear, PCR/ IgM and NS1 ELISA*P. vivax,* DENV4--8, DENV3--1, DENV2--18, DENV1--355Santana \[[@CR71]\]Novo Repartimento (Pará), BrazilMay 2003 to August 2005Cross sectional11122\>  18 yearsBlood smear/PCR*P. vivax,* DENV2N -- sample size, ML/DN - Malaria/Dengue coinfection, ELISA - Enzyme linked immunosorbent assay, NS1 - Dengue non-structural protein − 1, PCR - Polymerase Chain reaction, RDT - rapid diagnostic test, PRNT - Plaque reduction neutralisation test, RMAT - Rapaid malaria antigen test, NM - not mentioned, NA - not applicableTable 2Coinfection cases of Dengue and ChikungunyaS.No.CitationsPlaceYearStudy designNPositive for coinfectionCoinfection (%)AgeDiagnostic test DN/CKRemarksSouth Asia1.Afreen \[[@CR72]\]Delhi,\
India2014Cross sectional87910All agesNS1, IgM, IgG ELISA, PCR/ IgM ELISA, PCRDENV2 + CHIKV-5, DENV3 + CHIKV -2, DENV1 + CHIKV-1, DENV1 + DENV2+ CHIKV-12.Carey \[[@CR73]\]Vellore,\
India1964Cross sectional47782All agesVirus isolation\
Serological\
Complement fixation and Hemagglutination inhibition assay for both infectionNM3.Chahar \[[@CR74]\]Delhi,\
India2006Cross sectional6969All agesPCR/PCRDENV1, DENV3, DENV44.Galate \[[@CR75]\]Mumbai,  MaharashtraApril 2012-Oct. 2013Cross sectional200191013--60IgM ELISA/IgM ELISANM5.Hapuarachchi \[[@CR76]\]Sri Lanka2006Case report11NA70PCR/PCRNM6.Kalawat \[[@CR77]\]Tirupati,\
India2011Retrospective analysis7223All agesIgM ELISA / IgM ELISANM7.Kaur \[[@CR78]\]Delhi,\
IndiaAug-Dec. 2016Cross sectional6001522511--68IgM ELISA, NS1 ELISA, PCR/IgM ELISA, PCRNM8.Londhey \[[@CR79]\]Mumbai,\
IndiaJune 2010--April 2015Prospective observational study3003010All agesIgM ELISA, PCR/ IgM ELISA, PCRNM9.Mørch \[[@CR34]\]Assam, Bihar, Chhattisgarh, Maharashtra, Anantpur, Tamilnadu\
IndiaApril 2011--November 2012Cross sectional1564251.634 mean ageIgM, NS1 ELISA/IgM ELISANM10.Mukherjee \[[@CR80]\]Kolkata,\
IndiaJuly 2014-Oct. 2015Cross sectional3265316All agesIgM and NS1 ELISA, PCR/IgM ELISA, PCRDENV2, DENV411.Neeraja \[[@CR81]\]Hyderabad, Telangana2007Cross sectional71381NMIgG, IgM, PCR/PCRNM12.Paulo \[[@CR82]\]Potugal,\
Infected in India2016Case report11NA65PCR/IgM ELISADENV313.Rahim \[[@CR83]\]Dhaka, Bangladesh2017Case report11NA23 femaleNS1 ELISA/IgM ELISANM14.Saswat \[[@CR84]\]Khurda, Odisha\
Aurangabad,\
Maharashtra IndiaJuly-Dec. 2013Cross sectional2224319All agesNS1, IgM, IgG ELISA, PCR/IgM ELISA, PCRDENV215.Shaikh \[[@CR85]\]Karnataka,\
IndiaJuly 2010--June 2013Cross sectional65545328NMIgM ELISA/IgM ELISANM16.Schilling \[[@CR86]\]Chennai,\
IndiaSeptember 2008Case report11NA25NS1, IgM ELISA and IFA/IgM IFANM17.Taraphdar \[[@CR87]\]West Bengal, India2010Cross sectional5506812All agesIgM ELISA, PCR / IgM ELISA, PCRDENV2, DENV318.Kularatne \[[@CR88]\]Peradeniya, SrilankaDec. 2006-March 2007Cross sectional543515--74IgM ELISA, Hemagglutination inhibition/ IgM ELISA, Hemagglutination inhibitionNMAfrica19.Baba \[[@CR47]\]NigeriaJuly-Dec. 2008Cross sectional3106320All agesPRNT/PRNTNM20.Caron \[[@CR89]\]GabonSep 2007-Aug 2010Cross sectional4287371All agesPCR of partial E gene/ PCR of partial E1 geneDENV221.Dariano \[[@CR50]\]Bo, Sierra Leone2012--2013Cross sectional1260131All agesIgM, IgG, NS1 ELISA/IgM ELISANM22.Leroy \[[@CR90]\]GabonMarch--July 2007Cross sectional77381NMPCR/ PCRDENV223.Nkoghe \[[@CR91]\]Franceville, GabonFeb-July 2010Cross sectional433204.61--77PCR/PCRNM24.Parreira \[[@CR92]\]Portugal, infected in Luanda, AngolaJanuary 2014Case report11NAEarly 50sNS1 IgM, IgG ELISA, PCR/IgM ELISA, PCRDENV425.Ratsitorahina \[[@CR93]\]Tomasina,\
MadagascarJan-March 2006Cross sectional551018NMIgM ELISA, PCR/IgM ELISA, PCRDENV1Caribbean26.Edwards \[[@CR94]\]GuatemalaJune 2015Surveillance report1444632All agesPCR/ PCRDENV1--4, DENV2--40, DENV4--227.Omarjee \[[@CR95]\]Island of Saint MartinDec. 2013-\
Jan 2014Cross sectional1502161All agesIgM, IgG ELISA and PCR / IgM, IgG ELISA and PCRDENV1--10, DENV2--2, DENV4--4Southeast Asia28.Cha \[[@CR96]\]Osong korea Infected (2 in Philllipine, 1 Vietnam, 1 Indonesia, 1 East Timor)2009--2010Cross sectional4865111--70IgM ELISA, PCR/ IgM ELISA, PCRNM29.Chang \[[@CR97]\]Taipei China, infected in Singapore2009 AprilCase report11NA12IgM and IgG ELISA, PCR/ IgM and IgG ELISA, PCRDENV230.Khai Ming \[[@CR98]\]Rangoon, BurmaJuly 1970-Dec. 1972Cross sectional2060552.60--11HI, CF/HI, CFNM31.Laoprasopwattana \[[@CR99]\]Southern ThailandApril--July 2009Prospective Cohort study5012≤15IgM ELISA and Hemagglutination inhibition/IgM IFA, PCRNM32.Nayar \[[@CR100]\]Kinta,\
Malaysia2006Case report22NA22 and 28NS1, IgM ELISA, PCR/PCRDENV133.Ooi \[[@CR101]\]Selangor, Malaysia,2009Case report11NANMNM/Complete Genome sequencing of CHIKVDENV234.Phommanivong \[[@CR102]\]Champasak LaosJuly-Aug 2013Cross sectional40512.55--65PCR/PCRDENV2--3,\
DENV3--235.Tun \[[@CR103]\]Mandalay,\
MyanmarJuly--October 2010Cross sectional11676≤12IgM ELISA, PCR/IgM ELISA, PCRNMNorth America36.Kariyawasam \[[@CR104]\]Toronto, CanadaMay 2006-April 2007 and Feb 2013-March 2014Retrospective analysis130410.070--91PCR/PCRDENV-137.Lindholm \[[@CR105]\]Maryland,\
USADec 2013-May 2015Cross sectional26720.725--60IgM, IgG ELISA, PCR, PRNT/ IgM, IgG ELISA, PCR, PRNTNMSouth America38.Bocanegra \[[@CR106]\]Barcelona Spain Infected in south AmericaApril 2014--2015Retrospective4251234.6 mean ageIgM ELISA/IgM ELISA, PCRNM39.Brooks \[[@CR107]\]Santos,\
Brazil2017Case report11NA27IgM ELISA/IgM ELISANM40.Calvo \[[@CR108]\]Girardot,\
ColombiaFeb 2015Cross sectional84500--10IgM ELISA, PCR/PCRNM41.Carrillo-Hernández \[[@CR109]\]Norte de Santander, ColombiaAugust 2015 -- April 2016Cross sectional157127.626.81PCR/PCRNM42.Farrell \[[@CR110]\]Machala, Ecuador2015Case report11NA35IgM, IgG ELISA/PCRNM43.Gomez-Govea \[[@CR111]\]Nuevo leon,\
MexicoJan-Oct 2015Cross sectional1015531 median ageIgM ELISA/IgM ELISA, PCRNM44.Mercado \[[@CR112]\]Bogota, ColombiaSept 2014-Oct 2015Retrospective analysis58712NMIgM ELISA, PCR/PCRNM45.Rosso \[[@CR113]\]Cali,\
Colombia2015Case report11NA72PCR/ PCRDENV3Middle East46.Malik \[[@CR114]\]Al-Hudaydah, YemenOct 2010-March 2011Cross sectional13610.7NMIgM ELISA, PCR/IgM ELISANM47.Rezza \[[@CR115]\]Al-Hudaydah\
Yemen2012Cross sectional400143.5All agesIgM, IgG ELISA and PCR/ IgM, IgG ELISA and PCRDENV2 PredominantlyN -- sample size, DN/CK -- Dengue/Chikungunya coinfection, ELISA -- Enzyme linked immunosorbent assay, NS1 - Dengue non-structural protein −1, PCR -- Polymerase Chain reaction, IFA -- immunofluorescence assay, PRNT -- Plaque reduction neutralisation test, NM -- not mentioned, NA -- not applicableTable 3Coinfection cases of Malaria and ChikungunyaS.No.CitationsPlaceYearStudy designNPositive for coinfectionCoinfection(%)AgeDiagnostic test ML/CKRemarksSouth Asia1.Mørch \[[@CR34]\]Assam, Bihar, Chhattisgarh, Maharashtra, Anantpur, TamilnaduApril 2011--Nov 2012Cross sectional156420**1.3**34 mean ageIgM, NS1 ELISA/IgM ELISANMAfrica2.Ayorinde \[[@CR46]\]Ogun, NigeriaApril-May 2014Cross sectional60915All agesBlood smear, RDT, PCR/IgM ELISA*P. falciparum*3.Baba \[[@CR47]\]NigeriaJuly-Dec. 2008Cross sectional310216.7All agesBlood smear /PRNT*P. falciparum*4.Chipwaza \[[@CR49]\]Morogoro, TanzaniaMarch--May and Aug-Oct. 2013Cross sectional36420.62--13 yearsBlood smear / IgM and IgG ELISA,NM5.Dariano \[[@CR50]\]Bo, Sierra Leone2012--2013Cross sectional12601189All agesRDTs/IgM ELISANM6.Mugabe \[[@CR116]\]Quelimane MozambiqueFeb-June 2016Cross Sectional16321.228 median ageRDT /IgM ELISA, PCRNM7.Sow \[[@CR53]\]Kedougou, SenegalJuly 2009--March 2013Cross sectional13,84530.02All agesBlood smear, RDT/ IgM ELISA, PCR*P. falciparum*N -- sample size, ML/CK- Malaria/Chikungunya coinfection, ELISA -- Enzyme linked immunosorbent assay, NS1 - Dengue non-structural protein −1, PCR -- Polymerase Chain reaction, RDT -- rapid diagnostic test, PRNT -- Plaque reduction neutralisation test, NM -- not mentionedTable 4Coinfection cases of Malaria, Dengue and ChikungunyaS.No.CitationsPlaceYearStudy designNPositive for coinfectionCoinfection (%)AgeDiagnostic test ML/DN/CKRemarksSouth Asia1.Abdullah \[[@CR117]\]Delhi,\
India2016Case report11NA21Blood smear, RDT/PCR/IgM ELISA, PCR*P. vivax,* DENV32.Gupta \[[@CR118]\]Delhi,\
India2017Case report11NA55RDT/NS1, IgM ELISA/PCR*P. falciparum*3.Mørch \[[@CR34]\]Assam, Bihar, Chhattisgarh, Maharashtra, Anantpur, Tamilnadu IndiaApril 2011--Nove 2012Cross sectional156420.134 mean ageBlood smear/IgM, NS1 ELISA/IgM ELISANM4.Tazeen \[[@CR119]\]Delhi,\
India2016Case report11NA3Blood smear /PCR/PCR*P. vivax*Africa5.Dariano \[[@CR50]\]Bo, Sierra Leone2012--2013Cross sectional126040.3All agesRDTs/IgM, IgG, NS1 ELISA/IgM ELISANM6.Raut \[[@CR120]\]India\
Infected in Nigeria2014Case report11NA21Blood smear / NS1 ELISA, PCR/PCR*P. falciparum*N -- sample size, ML/DN/CK -- Malaria/Dengue/Chikungunya coinfection, ELISA -- Enzyme linked immunosorbent assay, NS1 - Dengue non-structural protein −1, PCR -- Polymerase Chain reaction, RDT -- rapid diagnostic test, NA -- not applicable, NM-not mentioned

Out of the 55 reports about Malaria/Dengue coinfections, only ten have reported the serotype of the Dengue virus. Out of the 47 reports about Dengue/Chikungunya coinfections 20 reports have mentioned the serotype of Dengue virus. Earliest report of Malaria/Dengue coinfection came in 2003 from Brazil, while earliest reported case of Dengue/Chikungunya coinfection came in 1964 from India. Malaria/Chikungunya cases were reported as late as 2008 from Nigeria. A retrospective matched pair study from French Guiana reported most cases (104) of Malaria/Dengue coinfections. Maximum cases of Dengue/Chikungunya coinfections (532) were reported from Karnataka in India and most cases of Malaria/Chikungunya coinfections (118) were reported from Bo, Sierra Leone.

Most cases of coinfections were reported from South Asia (52), primarily from India, followed by Africa (25), South-east Asia (16), South America (15), Caribbean (3) and Middle East (2). Two studies from North America reported coinfections of Dengue/Chikungunya in returning travellers without identifying the location where coinfections occurred. Malaria/Dengue coinfections were reported from 44 unique locations spread across 20 different countries (Fig. [2](#Fig2){ref-type="fig"}). Dengue/Chikungunya coinfections were reported from 48 unique locations spread across 26 countries (Fig. [3](#Fig3){ref-type="fig"}). 5 countries from African continent and India reported cases of Malaria/Chikungunya coinfections (Fig. [4](#Fig4){ref-type="fig"}). Cases of Malaria/Dengue/Chikungunya coinfections were reported from India, Sierra Leone and Nigeria (Fig. [5](#Fig5){ref-type="fig"}). Seven countries reported infection in returning travellers(Fig. [6](#Fig6){ref-type="fig"}). Based upon cross sectional studies Malaria/ Dengue prevalence varied widely, ranging between 0.1--23% from south Asia, 0.01--9% from Africa, 0.5--2.5% from Southeast Asia and 1--3% from South America. The frequency of Dengue/Chikungunya coinfections ranged from 1 to 25% from South Asia, 1--20% from Africa, 1--32% from Caribbean, 1--12.5% from Southeast Asia, 0.07--0.7% from North America, 5--50% from South America and 0.7--3.5% from Middle east. Malaria/Chikungunya coinfections frequency ranged from 0.02--15% from Africa and a single study reported from India reported 1.3% patients coinfected with both pathogens. Malaria/Dengue/Chikungunya coinfection frequency was reported by two cross sectional studies, one from India with 0.1% prevalence and another from Sierra Leone with 0.3% prevalence.Fig. 2Global distribution of Malaria/Dengue coinfectionsFig. 3Global distribution of Dengue/Chikungunya coinfectionsFig. 4Global distribution of Malaria/Chikungunya coinfectionsFig. 5Global distribution of Malaria/Dengue/Chikungunya coinfectionsFig. 6Countries from where coinfection cases were reported in returning travellers

Discussion {#Sec8}
==========

Malaria, Dengue and Chikungunya are arthropod borne diseases that have shared endemic profiles. These diseases are spread by mosquito vector, which are found in abundance in tropical regions of the world. *Anopheles* mosquito, which transmits Malaria parasite, is a night biting mosquito and breed in stagnant water \[[@CR121]\]. *Aedes* that spreads Dengue and Chikungunya, on the other hand bites in daylight and breeds in stored clean water \[[@CR122]\]. Expansion of the *Aedes* vector has lead to introduction of Dengue and Chikungunya to newer locations. Rapid urbanisation without the development of civic infrastructure, constant movement of population for livelihood, monsoon dependent breeding patterns and overlapping habitats have lead to co-circulation and coinfection of these pathogens in the same population \[[@CR123]\]. Diagnosis of cases of coinfection is compounded by the fact that initial symptoms of all three diseases are very similar that include febrility as the common factor. Several reports have been published that does not identify the coinfecting pathogen due to lack of distinguishing symptoms at the time, but retrospective analysis later revealed otherwise. In resource poor settings and during outbreaks clinicians might not have the resources or time to rely on detailed investigations.

We have attempted to identify regions of the world from where cases of mixed infection with Malaria, Dengue and Chikungunya have been reported. We searched the databases to identify published reports about any of these coinfections. Most reports of Malaria/Dengue and Dengue/Chikungunya coinfections were reported from India. In recent years there have been many outbreaks of Dengue and Chikungunya in India, not to mention that the first published report of Dengue/Chikungunya coinfection was reported from India in 1967 \[[@CR72]\]. However the overall percentage of Malaria/Dengue coinfections was low which, can be explained by different vector species for Malaria verses Dengue and Chikungunya. The highest frequency of Malaria/Dengue coinfections was reported from Pakistan that is endemic for both Malaria and Dengue. Lowest frequency was reported form Senegal with only 0.01%. 41 reports clearly identified the parasite species for Malaria infection but only 10 reported the serotype of Dengue virus. All four serotypes were found to exist with Malaria parasite. Coinfection cases were found in all age groups and gender. Nearly 85% of the reports for Malaria/Dengue coinfections have used microscopic confirmation of the Malaria parasite identifying the parasite load and species. Dengue infections were primarily detected by a combination of immunoglobulin ELISA, NS1 ELISA and PCR.

Dengue/Chikungunya coinfections were reported by 47 studies and an overall higher percentage as compared to Malaria/Dengue coinfection possibly because of similar vector species. The Highest frequency of Dengue/Chikungunya coinfections was reported from Colombia and lowest from Canada in returning travellers. Dengue virus serotype-4 was the predominant serotype found in cases of coinfections. Malaria/Chikungunya coinfections were rare with only 7 published reports. All of them were reported from Africa and India. 6 studies reported Malaria/Dengue/Chikungunya coinfections, four of them were case reports and two cross sectional studies. Three of the case reports were infected in Delhi while another one could have been infected in Nigeria or India. Delhi has become a hub of Industrial and social activities with a burgeoning population. Almost every year during monsoon season the city witnesses Dengue outbreaks with thousands of people getting infected. Due to the lack of distinguishing clinical features, laboratory diagnosis based on endemic patterns and outbreak reports are the only way for adequate clinical management of double or triple coinfections. At least 12 studies reported coinfections in returning travellers underlining the role of travel-based spread of the diseases. This phenomenon has been observed for SARS, MERS-CoV and Dengue \[[@CR124]--[@CR126]\]. Exposing a naïve population to new pathogens might lead to disease outbreak, not to mention viral mutations to adapt its human or mosquito host resulting in more pathogenic strain. Travel advisories and routine surveillance of returning travelers to endemic regions should be implemented stringently to control spread of infections.

Interaction of multiple pathogens within a host may potentially result in several different outcomes. Firstly, if the coinfecting organisms are dependent on similar tissues, the host may have to deal with multiple pathogens at the same time and place. Such interactions are likely to be detrimental to the host as happens in the case of coinfection with Hepatitis B, C and Delta virus coinfections. Hepatitis B, C and Delta virus coinfections results in severe chronic disease that responds poorely to the interferon alpha treatment \[[@CR127]\] as compared to single infections. Secondly, the immune effector mechanisms triggered by one pathogen may weaken or divert the host immunity leading to severe outcomes or increased resistance to therapy as exemplified in the case of infection with *Mycobacterium tuberculosis* and parasite coinfections \[[@CR128]\]. Thirdly, the coinfection may not have any serious effect on the prognosis of disease. However, even in such cases the misdiagnosis and mistreatment that may result, can be detrimental to the host. And finally, a coinfection may infact lead to better prognosis. For instance, it has been observed in the decreased mortality rate among the HIV patients coinfected with hepatitis G virus as compared to patients infected with HIV \[[@CR129]\]. *Plasmodium*, Dengue virus and Chikungunya virus all infect different cell types in humans and might influence immune effector mechanism by downregulationg proinflammaotry cytokines like IL-12 and IFN-γ \[[@CR11], [@CR130]\]. A proper clinical analysis of Malaria, Dengue and Chikungunya coinfection is necessary to form an informed opinion on following a treatment regimen that best supports the patient and leads to an early resolution of the infection. Out of 104 reports, there are very few reports that have actually looked at the disease severity by establishing proper controls and comparing it with cases of monoinfections systematically. For Malaria/Dengue coinfections, prolonged fever, thrombocytopenia, anemia, renal failure and Jaundice were more pronounced as compared to monoinfections. Dengue/Chikungunya coinfections can result in diarrahea, deep bleeding, hepatomegaly and overall increase in disease severity. High grade fever was the only distinguishing feature of Malaria/Chikungunya coinfection. More such studies are required to create a consensus about disease outcome in cases of coinfections. Animal models that can replicate the coinfection scenario would be very helpful in identifying severity patterns for these diseases.

The distribution of *Aedes* vector has been reported from Southeast Asia, South Asia, East, Central and West Africa, Caribbean and South America. *Aedes aegypti* and *Aedes albopictus* are responsible for the spread of Dengue, Chikungunya, West Nile, Yellow fever and Zika virus \[[@CR131]\]. It is difficult to distinguish whether cases of coinfection are due to separate mosquito bites delivering the viruses or single bite by mosquito harboring both viruses. The incubation period of both viruses is nearly same so both diseases are manifested around the same time. *Anopheles* has also been reported from the above-mentioned regions and also from East and central Asia, Europe and North America \[[@CR132]\]. Most cases of Malaria/Dengue and Malaria/Chikungunya coinfections were found from the regions where both vector species are present. In many instances a seasonal pattern of infections is observed with most cases being reported during monsoon season, which coincides with the breeding season of Mosquito vector. Climatic, sociodemographic and environmental factor play a crucial role in survivability and distribution of the mosquito vector thereby influencing cases of coinfections \[[@CR133]\]. Vector control continues to be an integral part of reducing disease burden but very few studies reported about the vectors responsible for cases of coinfection. Routine collection of vector surveillance data and thorough analysis of the role of vectors in coinfection cases need to be assessed.

Data collection is prone to bias, to this affect we have made every effort to search and analyze the current literature with broad search queries, nonetheless many relevant studies were unavailable due to lack of full text availability. Also the review relied completely on published literature where grey literature and studies with minimal or negative results may not have been included resulting in publication bias. Furthermore, studies obtained were of variable quality and many did not reported data on disease severity and outcomes in cases of coinfections. Despite these lacunas, the present study attempts to clearly identify regions of the world from where cases of coinfections were reported by thorough search and analysis of published reports. Our analysis indicates that coinfections with Malaria, Dengue and Chikungunya or in rare instances all three is a possibility. Our analysis also indicates that there are higher percentages of people with febrile symptoms, which might have Dengue/Chikungunya coinfections as compared to Malaria/Dengue or Malaria/Chikungunya coinfections. Shared epidemiology, vector distribution and co-circulation of pathogens are some of the reasons for coinfections. We have georeferenced cases of coinfections and identified affected countries of the worlds, establishing co-endemicity of these infections, which might help in proper and complete diagnosis of cases of coinfections with similar initial symptoms.

Conclusion {#Sec9}
==========

This systematic review has found evidence of Malaria, Dengue and Chikungunya coinfections in 42 Countries spread across several geographical locations. Malaria/Dengue was the most prevalent coinfection followed by Dengue/Chikungunya. These infections often affect same populations due to share endemicity and can be present simultaneously in the same individual. Similar initial symptoms make it harder for clinicians to identify cases of coinfections. Most coinfections were found from South Asia and Africa. *P. falciparum* and *P. vivax* were the most common malaria species found with coinfecting arbovirus and DENV-4 was the most common serotype found in cases of Dengue coinfections. Prolonged and high grade fever, thrombocytopenia, diarrhea, Jaundice and hepatomegaly were some of the signs and symptoms associated with cases of coinfection. We also found evidence of coinfections in returning travellers, which have the potential to introduce the pathogen into new locations with established vector populations. Our study highlights the global prevalence of cases of coinfection and their geographical distribution, which could help in systematic planning, surveillance, diagnosis and health care delivery to the affected population.

Additional file
===============

 {#Sec10}

Additional file 1:**Table S1.** Detailed search strategy. (DOCX 14 kb)

CHIKV

:   Chikungunya Virus

DENV

:   Dengue Virus

ELISA

:   Enzyme linked immunosorbent assay

MERS-CoV

:   Middle East respiratory syndrome corona virus

PCR

:   Polymerase chain reaction

SARS

:   Severe Acute Respiratory Syndrome
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